Abeona Therapeutics (ABEO) closed FY 2025 with Q4 revenue of US$5.4 million and basic EPS of a US$0.37 loss, alongside a net income loss of US$20.5 million. Its trailing twelve month figures show basic EPS of US$1.34 and net income of US$71.2 million on revenue of US$5.8 million. Over recent quarters the company has reported revenue of US$0 in Q3 2025, US$0.4 million in Q2, and US$5.4 million in Q4, with quarterly basic EPS moving from a US$2.07 profit in Q2 to losses of US$0.10 in Q3 and US$0.37 in Q4. That mix of improving trailing profitability and choppy quarterly margins gives investors several points to consider regarding the quality and durability of the current earnings profile.

See our full analysis for Abeona Therapeutics.

With the results on the table, the next step is to see how these reported margins and earnings trends compare with the widely held narratives around Abeona Therapeutics and where those narratives might be tested.

One off gain drives US$71.2 million profit

• Over the last 12 months, Abeona reported net income of US$71.2 million on US$5.8 million of revenue. This includes a US$152.4 million one off gain that heavily influences the profitability picture.
• Bulls point out that trailing earnings turned positive and have grown at 33.6% per year over five years. However, this hinges on:
  • Q2 FY 2025 net income of US$108.8 million on just US$0.4 million of revenue, which is unusually high relative to other quarters and lines up with the one off item.
  • The latest Q4 FY 2025 quarter showing a loss of US$20.5 million despite that profitable trailing 12 month figure, so the bullish view leans on forecasts rather than the most recent quarterly margin.

Consistent profits are still to be proven, which is exactly the tension bulls are trying to address in their thesis 🐂 Abeona Therapeutics Bull Case.

P/E of 3.6x versus 19.3x peers

• The shares trade on a trailing P/E of 3.6x compared with 20x for the US Biotechs industry and 19.3x for peers, while the current price of US$4.55 sits far below an indicated DCF fair value of US$86.09.
• Bears argue that this low multiple is explained by quality concerns around earnings and capital structure, and the data gives them several points:
  • Reported numbers fold in that very large US$152.4 million one off gain, so the P/E based on trailing earnings may not reflect ongoing profitability.
  • Shareholders also saw substantial dilution over the past year, which means per share outcomes can differ from headline profit growth even if total earnings look strong.

Skeptics question whether a low P/E really signals a bargain here or just bakes in the risks around dilution and one off gains 🐻 Abeona Therapeutics Bear Case.

Quarterly swings contrast with growth forecasts

• Across FY 2025, quarterly net income moved from a US$12.0 million loss in Q1 to a US$108.8 million profit in Q2, then back to losses of US$5.2 million in Q3 and US$20.5 million in Q4, while revenue went from US$0 to US$0.4 million and then US$5.4 million.
• The consensus narrative highlights very large forecast revenue growth of 38.6% per year and earnings growth of 30.3% per year, which sits in clear tension with:
  • The recent pattern of two loss making quarters out of the last three, even after one product approval is flagged in Q2 and Q3 FY 2025.
  • The fact that analysts also expect margins to compress from extremely high levels today over the next three years, so the path from these lumpy quarters to those smoother growth numbers is not yet reflected in the reported results.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Abeona Therapeutics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mix of caution and optimism throughout these results, it makes sense to check the underlying data yourself and decide where you stand. To move from headline figures to a fuller picture of strengths and pressure points, take a closer look at Abeona Therapeutics' 4 key rewards and 3 important warning signs

See What Else Is Out There

The reliance on a US$152.4 million one off gain, recent quarterly losses and shareholder dilution all raise questions about the consistency of Abeona Therapeutics' earnings.

If those swings in profitability and capital structure leave you uneasy, compare this profile with 74 resilient stocks with low risk scores to quickly focus on companies where financial risk scores already look more controlled.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.